In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 374554-89-9, name is 3-Chloro-6-fluorobenzo[d]isoxazole, introducing its new discovery. 374554-89-9
Pyrazolopyridine derivatives and their use as anti-inflammatory and/or anti-allergic agents
Compounds of formula (I) and pharmaceutically acceptable salts thereof: STR1 wherein: R1 is hydrogen, C1-6 alkyl or phenyl optionally substituted by halogen, CF3, C1-4 alkoxy or C1-4 alkyl; R2 is hydrogen or C1-6 alkyl; R3 is hydroxy, nitro, cyano, C2-10 acyloxy, NR6 R7 wherein R6 and R7 are independently selected from hydrogen, C1-6 alkyl, C2-7 alkanoyl or C1-6 alkylsulphonyl; or COR8 wherein R8 is hydroxy, C1-6 alkoxy or NR9 R10 wherein R9 and R10 are independently selected from hydrogen or C1-6 alkyl; R4 is hydrogen, halogen, CF3, C1-4 alkoxy, C1-4 alkyl or any of the groups listed for R3 ; and R5 is hydrogen, C1-4 alkyl or benzyl optionally substituted in the phenyl ring by halogen, CF3, C1-4 alkoxy or C1-4 alkyl and is attached at nitrogen atom 1 or 2, having anti-inflammatory and/or anti-allergy activity, and their use as pharmaceuticals.
Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.374554-89-9, you can also check out more blogs about374554-89-9
Reference£º
Benzisoxazole – Wikipedia,
Benzisoxazole – an overview | ScienceDirect Topics